Enliven worth goal lowered to $27 from $36 at JonesResearch
JonesResearch analyst Soumit Roy lowered the agency’s worth goal on Enliven (ELVN) to $27 from $36 and retains a Purchase score on the shares. The corporate’s summary from the Section 1 late line continual myeloid leukemia trial with ELVN-001 “was met with a lukewarm preliminary inventory response that weakened over time,” the analyst tells buyers in a analysis word. The agency says that although ELVN-001 confirmed efficacy and security profile inline with the September 2024 replace with two-times the affected person inhabitants, the market handled the inventory with a promote on information method. Jones sees ELVN-001 performing a minimum of inline with Novartis’ Scemblix.
Revealed first on TheFly – the last word supply for real-time, market-moving breaking monetary information. Attempt Now>>
See Insiders’ Sizzling Shares on TipRanks >>
Learn Extra on ELVN:
